Company Description
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally.
The company offers peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, and aspiration pump under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as detachable coils to treat patients with a wide range of neurovascular lesions under the Penumbra SMART COIL and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands.
In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products.
Further, it offers neurosurgical tools comprising Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum.
The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
| Country | United States |
| Founded | 2004 |
| IPO Date | Sep 18, 2015 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 4,500 |
| CEO | Adam Elsesser |
Contact Details
Address: One Penumbra Place Alameda, California 94502 United States | |
| Phone | 510 748 3200 |
| Website | penumbrainc.com |
Stock Details
| Ticker Symbol | PEN |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001321732 |
| CUSIP Number | 70975L107 |
| ISIN Number | US70975L1070 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Adam Elsesser J.D. | Co-Founder, Chairman, President and Chief Executive Officer |
| Dr. Arani Bose M.D. | Co-Founder and Director |
| Maggie S. Yuen | Chief Financial Officer |
| Lambert Shiu | Chief Accounting Officer |
| Johanna Roberts J.D. | Executive Vice President, General Counsel and Secretary |
| Ben Sorci | Executive Vice President of Operations |
| Pankaj Tiwari | Executive Vice President and Chief Information Officer |
| Jee Hamlyn-Harris | Investor Relations Officer |
| Ben Tompkins | Executive Vice President of Development and Compliance |
| Shruthi Narayan | President of Interventional |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2025 | 10-Q | Quarterly Report |
| Apr 23, 2025 | 8-K | Current Report |
| Apr 16, 2025 | 144 | Filing |
| Apr 16, 2025 | ARS | Filing |
| Apr 16, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 16, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 4, 2025 | PRE 14A | Other preliminary proxy statements |
| Apr 2, 2025 | 144 | Filing |
| Apr 2, 2025 | 144 | Filing |
| Apr 1, 2025 | 144 | Filing |